Golunski Grzegorz, Woziwodzka Anna, Piosik Jacek
Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland.
Curr Pharm Biotechnol. 2018;19(3):206-216. doi: 10.2174/1389201019666180528084641.
Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication. However, numerous research groups report that PTX also may potentially be used in the anticancer therapy following one of the main trends in the nowadays medicine - combined anticancer therapy.
The review concentrates on the reports revealing the potential use of PTX in cancer treatment. Major Conclusion: PTX is described to possess several properties which may be exploited in cancer treatment. The drug reportedly not only has anticancer activity itself, but also increases cancer cells susceptibility to radiation therapy and, additionally, reduces long-term side effects of this therapy. Furthermore, numerous research groups report that PTX may increase the anticancer potential of commonly used anticancer drugs such as cisplatin or doxorubicin as well as reduce side effects of these drugs.
PTX should be considered as a potential drug in the combined anticancer therapy.
己酮可可碱（PTX）是一种常用于治疗间歇性跛行的药物。然而，众多研究团队报告称，按照当今医学的主要趋势之一——联合抗癌疗法，PTX也可能潜在地用于抗癌治疗。
本综述聚焦于揭示PTX在癌症治疗中潜在用途的报告。
PTX被描述为具有多种可用于癌症治疗的特性。据报道，该药物不仅本身具有抗癌活性，还能增加癌细胞对放射治疗的敏感性，此外，还能降低这种治疗的长期副作用。此外，众多研究团队报告称，PTX可能会增加常用抗癌药物（如顺铂或阿霉素）的抗癌潜力，并减少这些药物的副作用。
PTX应被视为联合抗癌治疗中的一种潜在药物。
